ReviewAdvances in biochemical engineering/biotechnology2026
Bioreactor Design and Engineering for Cultivated Meat Manufacturing.
Review in Advances in biochemical engineering/biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioreactors encompass a wide spectrum of engineering concepts, yet for decades, industrial biotechnology has seen little fundamental innovation, with large-scale production mainly confined to stirred-tank and bubble-column reactors for microbial fermentations. In pharmaceutical biotechnology, various cultivation systems for eukaryotic cells are well established, including microcarrier processes, suspension in stirred vessels, and disposable bags or wave (rocking) bioreactors. However, these systems have typically been optimized to produce specific biomolecules, such as recombinant proteins, vaccines, or monoclonal antibodies, rather than for generating cellular biomass itself. The emergence of tissue engineering for medical applications brought new technological impulses, particularly in the development of scaffold materials and the spatial organization of cells in three-dimensional constructs. This was accompanied by advances in perfusion bioreactors, enabling sustained nutrient delivery and waste removal within thick tissue cultures. Such systems were designed for relatively small, high-value applications in regenerative medicine, but they provide valuable conceptual and technical groundwork for structured cultivated meat manufacturing. In cellular agriculture, the goal is to apply and adapt established bioprocessing knowledge to a new challenge: producing animal cells at food-relevant scales and costs. Rather than high-value, low-volume pharmaceutical production, the focus shifts to high-volume, cost-efficient food production. Achieving this will require interdisciplinary collaboration between bioprocess engineers, automation specialists, tissue engineers, cell biologists, and food technologists.
Indexed as
Identifiers
41844987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.